← The Wire
QURENasdaq
uniQure N.V.
Pharmaceutical Preparations · CIK 1590560
Develops single-treatment gene therapies with potentially curative results for devastating diseases
red 8-K · 90d🔥 High media attention
$1.74B
Market cap
$47.39
Last close
-0.3%
1D
+6.8%
5D
2.3M
Volume
Price · last 39 sessions+129.2%
May 4L $20.68 · H $49.10Jun 29
312
Total filings
Jun 24, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · Company UpdateJun 24, 2026424B5424B5Jun 24, 2026424B5424B5Jun 22, 20268-KReg FD Disclosure · Company UpdateJun 22, 20268-KCompany UpdateJun 17, 20268-KExecutive Change · Bylaw AmendmentJun 15, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 20268-KReg FD DisclosureApr 30, 2026DEFA14ADEFA14AApr 27, 2026DEF 14ADEF 14AApr 27, 202610-K10-KMar 2, 20268-KResults of Operations · Reg FD DisclosureMar 2, 20268-KReg FD DisclosureJan 13, 20268-KReg FD DisclosureJan 9, 20268-KReg FD Disclosure · Company UpdateDec 4, 202510-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KReg FD Disclosure · Company UpdateNov 3, 20258-KMaterial Agreement · Company UpdateSep 29, 2025424B5424B5Sep 29, 2025424B5424B5Sep 24, 20258-KMaterial Agreement · New Debt / ObligationSep 24, 20258-KReg FD Disclosure · Company UpdateSep 24, 20258-KMaterial AgreementJul 29, 2025424B5424B5Jul 29, 202510-Q10-QJul 29, 20258-KResults of OperationsJul 29, 20258-KExecutive Change · Shareholder VoteJun 13, 20258-KReg FD DisclosureJun 2, 202510-Q10-QMay 9, 20258-KResults of OperationsMay 9, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 20258-KExecutive ChangeApr 16, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 20258-KMaterial Agreement · Company UpdateJan 8, 2025424B5424B5Jan 8, 2025424B5424B5Jan 7, 20258-KReg FD DisclosureDec 10, 20248-KReg FD DisclosureNov 21, 202410-Q10-QNov 5, 20248-KResults of OperationsNov 5, 20248-KReg FD DisclosureOct 15, 20248-KReg FD DisclosureSep 23, 20248-KReg FD DisclosureAug 15, 20248-KResults of OperationsAug 1, 202410-Q10-QAug 1, 20248-KExecutive Change · Material AgreementJul 23, 2024SC 13GSC 13GJul 18, 20248-KReg FD Disclosure · Company UpdateJul 9, 20248-KMaterial Agreement · Reg FD DisclosureJul 1, 20248-KExecutive Change · Shareholder VoteJun 20, 20248-KReg FD DisclosureJun 3, 20248-KResults of OperationsMay 7, 202410-Q10-QMay 7, 2024DEFA14ADEFA14AApr 24, 2024DEF 14ADEF 14AApr 24, 20248-KExecutive ChangeApr 12, 20248-KResults of OperationsFeb 28, 202410-K10-KFeb 28, 2024SC 13GUNIQURE N.V.Feb 13, 20248-KReg FD Disclosure · Company UpdateDec 19, 20238-KExecutive Change · Shareholder VoteNov 17, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 2023DEFA14ADEFA14AOct 6, 2023DEF 14ADEF 14AOct 6, 20238-KExecutive Change · Exit / Disposal CostsOct 5, 20238-KResults of OperationsAug 1, 202310-Q10-QAug 1, 20238-KReg FD Disclosure · Company UpdateJun 22, 20238-KShareholder VoteJun 16, 20238-KMaterial Agreement · New Debt / ObligationMay 16, 20238-KResults of OperationsMay 9, 202310-Q10-QMay 9, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 20238-KExecutive ChangeApr 5, 2023
Insider Activity
In the 90 days to Mar 4, 2026: 6 sold $2.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2026 | Kapusta Matthew CCEO, Managing Director | Sell | 14,581 | $9.06 | $132K |
| Mar 4, 2026 | Klemt ChristianChief Financial Officer | Sell | 12,000 | $9.06 | $109K |
| Mar 4, 2026 | Potts JeannetteChief Legal Officer | Sell | 3,412 | $9.06 | $31K |
| Mar 4, 2026 | Abi-Saab WalidChief Medical Officer | Sell | 808 | $9.06 | $7K |
| Mar 2, 2026 | Kapusta Matthew CCEO, Managing Director | Sell | 34,437 | $9.95 | $343K |
| Mar 2, 2026 | Klemt ChristianChief Financial Officer | Sell | 12,532 | $9.95 | $125K |
| Mar 2, 2026 | Potts JeannetteChief Legal Officer | Sell | 8,578 | $9.95 | $85K |
| Mar 2, 2026 | Abi-Saab WalidChief Medical Officer | Sell | 1,660 | $9.95 | $17K |
| Feb 25, 2026 | Kapusta Matthew CCEO, Managing Director | Sell | 12,378 | $23.86 | $295K |
| Feb 25, 2026 | Klemt ChristianChief Financial Officer | Sell | 6,217 | $23.86 | $148K |
| Jan 12, 2026 | Gut RobertDirector | Sell | 17,310 | $24.39 | $422K |
| Jan 12, 2026 | Gut RobertDirector | Sell | 7,803 | $25.09 | $196K |
| Jan 12, 2026 | Gut RobertDirector | Sell | 500 | $25.03 | $13K |
| Jan 9, 2026 | Kaye JackDirector | Sell | 6,390 | $27.28 | $174K |
| Nov 6, 2025 | Gut RobertDirector | Sell | 15,840 | $27.22 | $431K |
| Nov 6, 2025 | Gut RobertDirector | Sell | 15,594 | $27.30 | $426K |
| Nov 4, 2025 | Kaye JackDirector | Sell | 17,810 | $30.33 | $540K |
| Nov 4, 2025 | Kaye JackDirector | Sell | 11,000 | $30.34 | $334K |
| Nov 4, 2025 | Kaye JackDirector | Sell | 10,000 | $30.36 | $304K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 7 reputable articles.
Investor's Business DailyWhy Biotech Stocks Are Celebrating This Nail-Biter12d agoInvestor's Business DailyUniQure Catapults Nearly 80% On A Gene Therapy Shock From The FDA12d agoBarron'sUniQure Stock Surges 81% as FDA Does About-Face on Gene Therapy Treatment12d agoCNBCStocks making the biggest moves midday: SpaceX, JPMorgan, UniQure, Intel, Figma, Nano Nuclear & more12d agoReutersUniQure to seek approval for Huntington's therapy after FDA U-turn, shares skyrocket13d agoBloomberg.comUniQure Shares Soar After FDA Reversal on Its Huntington’s Therapy13d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance